The India, Pakistan & Cambodia HEPATITIS C VIRUS (HCV) Treatment Market is expected to grow at a CAGR during the forecasting period (2022-2029).
Hepatitis C Virus (HCV) is an infection that affects the liver which may lead to serious consequences if not taken care of. It spreads through infected blood transfusions and poorly sterilized medical equipment.
The number of patients has increased significantly because its symptoms take time to be recognized before the patient progresses towards clinically visible liver damage which worsens the situation since it may lead to liver damage or even failure.
There was no proper therapy for HCV before 2010 but the coming of therapies like Sovaldi and Harvoni by Gilead and Viekira Pak by AbbVie has improved the scenario. Also, the steps taken like proper blood screening is helping in identifying the patients.
Some of the major players include: AbbVie Inc., Gilead Sciences, Inc., Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc, Merck, F. Hoffmann-La Roche Ltd, among other
Get your free sample proposal with a single click!